⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2881366 | 1.00 | — | — | |
| SCHEMBL2876822 | 1.00 | — | — | |
| SCHEMBL4380167 | 0.93 | CXCR4 (0.46) | — | |
| SCHEMBL2116772 | 0.87 | HRH3 (0.46) | — | |
| SCHEMBL23828668 | 0.81 | HRH3 (0.52) | — | |
| SCHEMBL23828676 | 0.81 | HRH3 (0.52) | — | |
| SCHEMBL2115515 | 0.81 | CXCR4 (0.51) | — | |
| SCHEMBL23828666 | 0.79 | HRH3 (0.50) | — | |
| SCHEMBL15473825 | 0.79 | — | — | |
| SCHEMBL15473898 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215504-A1 | NOVEL 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-09-13 | — | — | EP | claimed |
| US-9637485-B2 | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-05-02 | — | — | US | claimed |
| WO-2016071215-A1 | NOVEL 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-12 | — | — | WO | claimed |
| US-20160122344-A1 | Novel 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-05-05 | — | — | US | claimed |
| EP-0764150-B1 | PRODUCTION OF HYDROXYTHIOACETAMIDES AND USE THEREOF IN THE SYNTHESIS OF BENZOTHIOPHENES | LILLY CO ELI (US) | 1999-10-27 | — | — | EP | claimed |
| EP-3215504-B1 | 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-08-21 | — | — | EP | disclosed |
| EP-3215504-A1 | NOVEL 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-09-13 | — | — | EP | disclosed |
| US-9637485-B2 | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| WO-2016071215-A1 | NOVEL 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-12 | — | — | WO | disclosed |
| US-20160122344-A1 | Novel 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-05-05 | — | — | US | disclosed |
| US-8338460-B2 | 3-({4-[2-(dimethylamino)ethoxy]phenyl}thio)-N-(3-methyl-1,2,4-thiadiazol-5-yl)-6-[(4-methyl-4H-1,2,4-triazol-3-yl)thio]pyridine-2-carboxamide; glucokinase activator; antidiabetic, obesity | MSD K. K. (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20100261699-A1 | N-PYRAZOLE-2-PYRIDINE CARBOXAMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7365196-B2 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK SHARP & DOHME LTD. (GB) | 2008-04-29 | — | — | US | disclosed |
| US-20080090799-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING EFFECT | MSD K.K. (JP) | 2008-04-17 | — | — | US | disclosed |
| EP-1453492-B1 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | EP | disclosed |
| US-7157467-B2 | Administering compound such as 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline for therapy of an autoimmune disease or medical condition selected from transplant rejection and rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-02 | — | — | US | disclosed |
| EP-1268412-B1 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-7115615-B2 | Quinazoline derivatives | ASTRAZENECA (SE) | 2006-10-03 | — | — | US | disclosed |
| US-20050014773-A1 | Therapeutic use | ASTRAZENACA AB (SE) | 2005-01-20 | — | — | US | disclosed |
| US-20040029862-A1 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK CANADA INC. (CA) | 2004-02-12 | — | — | US | disclosed |